EUVIMEDEUVIMED entdecken
Crossref

Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients

Tanguy Bouget, Marine Lottin, Abeer Najem, Sahir Javed, Marine Marrucho, Julien Elices-Diez, Pierre-Yves Cren, Marie-Cécile Le Deley, Nicolas Penel, Aurélien Carnot, Gautier Marcq, Alexandra Forestier

Oncology · 16.07.2026 · 1-12

DOI: 10.1159/000552741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 16.07.2026. Verfasst von Tanguy Bouget und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Médecine, Université de Lille, Lille, France, tanguyb@live.fr. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) are widely prescribed as the first-line treatment for metastatic renal clear-cell carcinoma because of their overall survival (OS) benefits. However, ICIs are associated with unreliable efficacy and sometimes severe and unpredictable toxicities. There is a lack of biomarkers for efficacy or toxicity beyond the IMDC score. Body composition (fat and muscle mass) may also be a biomarker of interest. The aim of this retrospective study was to analyze the association between body composition, OS, and toxicities in patients with RCC treated with ICI as a first-line metastatic treatment.

Methods

Body composition parameters – subcutaneous fat index (SFI), visceral fat index (VFI), total fat index (TFI), and skeletal muscle index (SMI) – were measured on computed tomography scans using semiautomated software.

Results

In 71 patients, no significant association was found between TFI and OS (adjusted HR, 0.71 [0.35; 1.45]) or toxicities. The TFI was strongly correlated with BMI (r = 0.81), whereas the SFI and VFI were weakly correlated.

Conclusion

Larger studies would be valuable to better define the thresholds of different parameters (SFI, VFI, TFI, and SMI) and their association with the efficacy and toxicity of ICI.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersFat massImmune checkpoint inhibitorsMuscle massRenal cell carcinoma

Autor:innen und Institutionen

  • Faculté de Médecine, Université de Lille, Lille, France, tanguyb@live.fr.
  • Service d'oncologie médicale, CHU Amiens-Picardie, Amiens, France.
  • Département d'oncologie médicale, Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, France.
  • Département d'oncologie médicale, Centre Hospitalier de Valenciennes, Valenciennes, France.
  • Département d'oncologie médicale, Centre Hospitalier de Roubaix, Roubaix, France.
  • Faculté de Médecine, Université de Lille, Lille, France.

Zitieren

APA

Bouget, T., Lottin, M., Najem, A., Javed, S., Marrucho, M., Elices-Diez, J., Cren, P. Y., Le Deley, M. C., Penel, N., Carnot, A., Marcq, G., & Forestier, A. (2026). Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients. Oncology, 1-12. https://doi.org/10.1159/000552741

Vancouver

Bouget T, Lottin M, Najem A, Javed S, Marrucho M, Elices-Diez J, et al. Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients. Oncology. 2026:1-12. doi:10.1159/000552741

BibTeX
@article{Bouget2026,
  author = {Bouget, Tanguy and Lottin, Marine and Najem, Abeer and Javed, Sahir and Marrucho, Marine and Elices-Diez, Julien and Cren, Pierre-Yves and Le Deley, Marie-Cécile and Penel, Nicolas and Carnot, Aurélien and Marcq, Gautier and Forestier, Alexandra},
  title = {Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients},
  journal = {Oncology},
  year = {2026},
  pages = {1--12},
  doi = {10.1159/000552741}
}
Kostenlos starten →